Top Paracetamol DMF Holder companies | Top 7 Pharma Database company
1.Pfizer In
Pfizer's 2018 sales hit $53.6 billion, boosted by operating revenue growth of 2 percent. This rise in revenues was driven by key product sales, including Ibrance, Eliquis, and Xeljanz, as well as operational growth in emerging markets.
In December 2018, Pfizer and GSK announced plans to merge their consumer healthcare companies into a new joint venture called GSK Consumer Healthcare. Pfizer will retain equity in the new company at 32 percent, while GSK will retain the remaining stake.
Pfizer is a diversified pharmaceutical company headquartered in the United States, with a range of biologics, vaccines, small molecular drugs, and consumer products.
Chemxpert Database is the world's first knowledge portal for buyers and suppliers for the entire Lifesciences industry. We are Paracetamol DMF Holder c the most creative online resource in the world using our own data analysis algorithms and professional data sources.You can search, analyze, and download any buyer and provider data with a few easy clicks using our own buyer and supplier database and reach your specifications. Our services are offered at extremely affordable prices and the best value for money in the sector.Our customers generally use it to find tools and business leaders as a raw materials provider. The Chemxpert Database understands that business objectives can not be achieved by data alone. It definitely starts working together to create the most personalized approach to the essence of your business strategies and fulfill these needs. With technical data, we believe this human-centered approach makes a difference for your company
Email-sales@lifescienceintellipedia.com
Swiss healthcare firm F Hoffmann-La Roche posted revenues of CHF56.84bn ($57.73bn) in 2018. The pharmaceutical division contributed much of CHF44bn ($44.68bn) of sales.
The pharmaceutical division 's revenues increased by 7 percent year-on-year due to the launch of new Ocrevus drug, as well as existing oncology medicines such as Perjeta, Tecentriq, Alecensa and Hemlibra.
The company posted a 14 percent rise in US revenue, while European sales were down 7 percent due to biosimilar competition.
Hoffmann-La Roche is a Swiss healthcare company that operates in two divisions: Pharmaceuticals and Diagnostics.
4.Merck & Co Inc
In 2018, Merck & Co recorded revenues of $42.3 billion, 5 per cent higher than the previous year. Increasing sales of key products like Keytruda and Gardasil was the major contributor to growth in the pharmaceutical division, which posted $9.8bn in revenues.
The division of animal health reported revenues of $1billion. In December 2018, Merck announced plans to acquire Antelliq Group which is expected to improve its role in the market for animal health.
New Jersey-based, US-based Merck & Co (known outside the US as MSD) offers pharmaceuticals, vaccines, and products for animal health.
In 2018, GSK recorded revenues of £30.82bn ($40bn) with the Pharmaceuticals Division contributing the highest revenues of £17.27bn ($22.4bn). Sales in the division of vaccinations rose by 14% to £5.9bn ($7.6bn), while sales of consumer healthcare decreased by 1% to £7.65bn ($9.95bn).
Geographically, US profits were the highest at £11.98 billion ($15.57 billion), while foreign sales stood at £10.86 billion ($14.12 billion). During the year, the company acquired TESARO, an oncology-focused company based in the US, to improve its pharmaceutical business, in particular its oncology pipeline.
GlaxoSmithKline (GSK) is a pharmaceutical company based in the UK that sells pharmaceuticals, vaccines and consumer healthcare as.
Strong immunology revenues and a pipeline of rare blood disorder medicines helped Sanofi Genzyme's specialty care division sales record a 30.8 percent increase in 2018 compared with the previous year.
The acquisition of Bioverativ and Ablynx during the year further expanded Sanofi's pipeline of rare blood disorder drugs. The acquisitions are expected to strengthen its potential for biological discovery.
Sales of vaccines also rose by 2.4%, although sales of diabetes and cardiovascular products dropped by 13.8%. Sales increased by 7.5 per cent in emerging markets , particularly China. In 2018, Sanofi, based in France, recorded net revenues of € 34.46 billion ($39.23 billion)
7.AbbVie Inc
In 2018, AbbVie achieved revenues of $32.73 billion , an increase of 15.2 per cent compared to the previous year. Growth in revenue was driven by strong sales of the company's immunology and oncology drugs including Humira and Imbruvica, which rose by 7.4% and 39.5% respectively.
Sales of the hematologic oncology portfolio of AbbVie were $3.93bn, a 45.9 percent jump, while those of the portfolio of hepatitis C viruses reached $3.61bn.
AbbVie is a biopharmaceutical company based in Illinois, USA which specialises in immunology, oncology, virology and neuroscience therapies.
Comments
Post a Comment